Free Trial
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

Cortexyme logo
$1.04 0.00 (0.00%)
As of 05/30/2025

About Cortexyme Stock (NASDAQ:CRTX)

Key Stats

Today's Range
$1.01
$1.05
50-Day Range
$0.84
$1.40
52-Week Range
$1.78
$40.66
Volume
102,293 shs
Average Volume
620,672 shs
Market Capitalization
$31.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Crism Thera Regulatory News
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Headlines

CRTX Stock Analysis - Frequently Asked Questions

Cortexyme's stock was trading at $1.85 at the beginning of 2025. Since then, CRTX shares have decreased by 43.8% and is now trading at $1.04.
View the best growth stocks for 2025 here
.

Cortexyme, Inc. (NASDAQ:CRTX) posted its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.05.

Cortexyme (CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

Last Earnings
8/09/2021
Today
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$89.94 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.26

Miscellaneous

Free Float
21,739,000
Market Cap
$31.36 million
Optionable
Not Optionable
Beta
1.40

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:CRTX) was last updated on 6/2/2025 by MarketBeat.com Staff
From Our Partners